End-stage renal disease (ESRD) and renal-replacement therapy in our country as it is all over the world in the most preferred with form bicarbonate hemodialysis. The 19-nor1 itamini analog of D v 0.25-dihyroxyvitamin D2 (paricalcitol) in the use of hemodialysis as we have encountered an increasing preparate. This prescription drug is likely to bring additional costs by reason, is limited to reimbursement by insurance companies. In this study, serum Ca values, instead of using the value of serum correcrtedCa paricalcitol and this situation will be reviewed possible changes, see if it will be statistically significant. K / DOQI guide based on the study, 19-nor1 dihyroxyvitamin 0.25-D2 (paricalcitol) in prescription, correctedCa revealing whether the use is necessary. Hemodialysis centers and eight months in a special configuration, this study inclusion criteria was carried out with the participation of a total of 35 adult patients. In the blood serum of patients, albumin, iPTH, Ca and P 'is a look at "paricalcitol" treatment can be started, and this situation can not be taken into account when correctedCa fact if the differences of views can occur. Levels of serum Ca 9.2 mg / dl values in the prescription, 10.2 mg / dL, treatment was considered as the cut-off threshold (Turkey, institution of insurance reimbursement-2008). Patients were evaluated in four main groups, statistical studies were done. The groups this study; group A: the most in December 2008 on vitamin D treated 23 patients, 30% and least in June 2009 in 27 patients, 20%, paricalcitol prescription in writing correctedCa is running varied. Group B: total number of patients in this group of eight months were identified as 5. Group C: serum Ca value taken into account when paricalcitol prescribing criteria that match all on a monthly basis the total number of patients, and February, 28 patients and through most of June the 20 patients, at least as have been identified. Group D: serum albuminin'e correctedCa value calculated by taking into account patients' prescriptions to be written, consists of monthly total. Minimum number of patients in this group was 16 December 08'de most patients were found to be 25 in February 09'da. In Group C and Group D, the statistical study, p <0.05 as statistically significant results were found. During eight months in adult hemodialysis patients this study shows that the serum Ca value of paricalcitol instead of always writing a prescription, the serum should be used for correctedCa. Perhaps the most important data to confirm these results, no doubt the magnitude of the difference between group C and group D was statistically significant and it is formed (p <0.05).